Catherine F. Cabot

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

Robert Altman, L Carreras, Rubén Sierra Díaz et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1994 · 3.3K citations

Medicine, Pharmacology, Pharmacotherapy +10

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

A. Michael Lincoff, Robert M. Califf, David J. Moliterno et al. · New England Journal of Medicine · 1999 · 379 citations

Medicine, Cardiology, Pharmacotherapy +17

Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial

Eric J. Topol, Daniel B. Mark, A. Michael Lincoff et al. · The Lancet · 1999 · 329 citations

Medicine, Cardiology, Pharmacoeconomics +16

Sustained Suppression of Ischemic Complications of Coronary Intervention by Platelet GP IIb/IIIa Blockade With Abciximab

A. Michael Lincoff, James E. Tcheng, Robert M. Califf et al. · Circulation · 1999 · 157 citations

Medicine, Cardiology, Pharmacotherapy +15

Standard Versus Low-Dose Weight-Adjusted Heparin in Patients Treated With the Platelet Glycoprotein IIb/IIIa Receptor Antibody Fragment Abciximab (c7E3 Fab) During Percutaneous Coronary Revascularization

A. Michael Lincoff, James E. Tcheng, Robert M. Califf et al. · The American Journal of Cardiology · 1997 · 139 citations

Medicine, Cardiology, Hematology +17